MedTrace Logo

Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease

NCT05752968 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2024-03-01

No results posted yet for this study

Summary

Background

Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. A cross-sectional study will be carried out the evaluate the possible association endotoxin core antibody with asymptomatic PAD in a cohort of HD patients.

Methods

This cohort study enrolled 500 HD patients treated at a single center in Taichung city. Fasting blood samples will be collected to determine biochemical data Endotoxin core antibody levels and other related biomarkers. By the automatic oscillometric method, the ankle-brachial index (ABI) was measured. Low ABI was defined as any value \< 0.9.

Conditions

  • Endotoxemia
  • Peripheral Arterial Disease

Sponsors & Collaborators

  • Tungs' Taichung Metroharbour Hospital

    lead OTHER

Principal Investigators

  • Paik Seong Lim, PhD · Tungs' Taichung Metroharbour Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05752968 on ClinicalTrials.gov